At the time of the event, there was no indication of a reportable malfunction based on information provided and assessed by alere (b)(4).Alere (b)(4) updated reporting decisions and conducted a retrospective review of complaints against the updated reporting decisions.This mdr is a retrospective filing that was identified during this retrospective review activity associated with an observation from an fda inspection conducted in january 2019 at alere (b)(4) (reference eir (b)(4)).The awareness date is based on updated reporting decisions and completion of the retrospective review activity.There is no new or increased trend based on this retrospective review activity.Investigation results: the customer's observation was not replicated in-house with retention products of the reported lot.Retention products were tested with qc cut-off hcg urine standards and clinically negative urine samples.All devices tested with qc cutoff standards showed positive results at read time meeting qc specifications.Additionally, devices tested with clinically negative urine samples showed expected negative results at read time.No false results were obtained during in-house testing.Manufacturing batch record review did not uncover any abnormalities.Root cause could not be determined based on the information provided.
|